Physician

Mark Knapp, MD

According to 2025 Medicare claims, Mark Knapp, MD (NPI: 1952359549) practices hematology/oncology in the Columbus, OH market, with the plurality of this provider's patient population coming from Franklin, OH. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 43219-1530.

Knapp's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 412 traditional Medicare patients, billed 59,176 HCPCS/CPT codes, and received $1,206,555 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 882 prescription claims across 162 beneficiaries totaling $6,526,759 in drug costs, led by Revlimid (Lenalidomide). 2019 DME data shows 11 claims. Open Payments data shows 33 records totaling $16,990. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $852,835 to $6,526,759. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	386	102,762	$861,445
2016	425	130,458	$983,641
2017	376	99,838	$795,096
2018	358	76,826	$922,495
2019	445	78,045	$1,105,756
2020	348	74,719	$1,193,959
2021	351	87,534	$1,245,453
2022	416	75,692	$1,174,689
2023	511	80,081	$1,136,567
2024	412	59,176	$1,206,555

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	179	976	$852,835
2016	190	884	$1,089,518
2017	146	820	$1,388,655
2018	159	858	$1,661,752
2019	174	891	$1,760,708
2020	161	932	$2,172,676
2021	168	909	$3,425,687
2022	167	834	$3,508,566
2023	162	768	$3,814,496
2024	162	882	$6,526,759

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	66	$4,315
2016	N/R	52	$1,131
2017	N/R	39	$7,598
2018	N/R	97	$12,712
2019	N/R	11	$1,889
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	179	385	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	230	320	$55
36415	Insertion of needle into vein for collection of blood sample	247	819	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	266	953	$8
85045	Red blood count, automated test	44	49	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	111	2,892	$1,922,019
Pomalyst	Pomalidomide	34	952	$779,267
Imbruvica	Ibrutinib	36	1,026	$569,558
Jakafi	Ruxolitinib Phosphate	23	690	$371,568
Brukinsa	Zanubrutinib	25	750	$353,361

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	30	$15,136	Pharmacosmos Therapeutics Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$1,854	Takeda Pharmaceuticals U.S.A., Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark Knapp, MD?

Tedicare shows public-source Medicare data for Mark Knapp, MD (NPI 1952359549), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Knapp, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark Knapp, MD?

Mark Knapp, MD is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Mark Knapp, MD have Open Payments data?

Mark Knapp, MD has 33 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.